Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this exploratory phase II study is to assess the effectiveness and safety
profile of Endostar®(Recombinant Human Endostatin Injection) plus Gemcitabine and Docetaxel
in treatment of soft tissue sarcoma patients with pulmonary metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Peng Yuan
Treatments:
Docetaxel Endostar protein Endostatins Gemcitabine